Novelties by EMA on medicinal products with genetically modified cells
Updated EMA guideline for medicinal products containing genetically modified cells provides innovations, recommendations and improvements to be ...
Toxicological assessment gain acceptance for cleaning validation
WHO publishes decision on setting acceptance criteria for cleaning validation
FDA approves Breyanzi®, a new CAR-T cell therapy drug
Fourth approved CAR-T cell therapy soon to be available in Europe?
Vaccinations with mRNA-based medicinal products
How do mRNA-based medicinal products work and how safe are they?
Integrated Qualification and Validation Guide
New ECA guide helps saving time and money by customer-supplier partnership on qualification and validation.
Nitrosamines in active substances and finished medicinal products
EMA strongly requests the risk-based proof that active substances and finished medicinal products are free of nitrosamines. Are you prepared for this?
Valicare Extends GxP Expertise
New Consulting Services for the Transition from Development to Clinical Manufacturing
MSC & Covid-19
In order to identify approaches to manage the current Covid-19 pandemic, the therapeutic use of mesenchymal stromal cells (MSCs) is increasingly ...
FDA opens up approval process for RYONCYL™
Mesoblast Ltd, headquartered in Australia with subsidiaries in the USA and Singapore, develops and distributes innovative allogenic cell therapeutics ...
FDA approves CAR T-cell therapy Tecartus™
On July 24, 2020, the US health authority FDA approved Tecartus™ (formerly KTE-X19) a cell-based gene therapy based on the chimeric antigen receptor ...
Use public funding for consulting services!
We’re in! Valicare is now an official BAFA-consultant and can tell you how consulting costs for small and medium-sized companies can be reduced.